Oryzon Genomics Competitors and Similar CompaniesClear all
Oryzon Genomics's competitors and similar companies include FORMA Therapeutics, Rein Therapeutics, Barinthus Biotherapeutics and Antikor.
 Oryzon Genomics Oryzon Genomics is a clinical stage biopharmaceutical company that discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. |  FORMA Therapeutics FORMA Therapeutics is a biopharmaceutical company intended for the discovery, development, and commercialization of transformative medicines. |  Rein Therapeutics Rein Therapeutics (formerly known as Aileron Therapeutics) is a clinical-stage biopharmaceutical company that develops medicines targeting undruggable cancer sites using its proprietary platform of stabilized cell-permeating peptides. |  Barinthus Biotherapeutics Barinthus Biotherapeutics (formerly known as Vaccitech) is a T-cell immunotherapy company developing products to treat and prevent cancer and infectious diseases. |  Antikor Antikor is a biotechnology company that specializes in the discovery and development of small-format antibody-drug conjugates. | |
Founding Date | Founding Date 2000 | Founding Date 2008 | Founding Date 2005 | Founding Date 2016 | Founding Date 2014 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations Cornellà de Llobregat, ES HQ Madrid, ES Cambridge, US | Locations Watertown, US HQ | Locations Watertown, US HQ Boston, US | Locations Oxford, GB HQ | Locations Stevenage, GB HQ |
Employees | Employees 47 | Employees 77 | Employees 838% decrease | Employees 33 | Employees 11 |
Valuation ($) | Valuation ($) 115.5 m | Valuation ($) 998.7 m | Valuation ($) 90.2 m | Valuation ($) 57.2 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods €282k (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit €434k (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit $16k (FY, 2025) | Gross profit N/A |
Net income | Net income (€2.6m) (FY, 2025) | Net income ($173m) (FY, 2021) | Net income ($49.9m) (FY, 2025) | Net income ($66.5m) (FY, 2025) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 142.5m | Total funding raised $ 112m | Total funding raised $ 195.1m | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
FORMA Therapeutics
HQ
Watertown, US
Employees
77
FORMA Therapeutics is a biopharmaceutical company intended for the discovery, development, and commercialization of transformative medicines.
View companyRein Therapeutics
HQ
Watertown, US
Employees
8↓ 38% decrease
Rein Therapeutics (formerly known as Aileron Therapeutics) is a clinical-stage biopharmaceutical company that develops medicines targeting undruggable cancer sites using its proprietary platform of stabilized cell-permeating peptides.
View companyBarinthus Biotherapeutics
HQ
Oxford, GB
Employees
33
Barinthus Biotherapeutics (formerly known as Vaccitech) is a T-cell immunotherapy company developing products to treat and prevent cancer and infectious diseases.
View companyAntikor
HQ
Stevenage, GB
Employees
11
Antikor is a biotechnology company that specializes in the discovery and development of small-format antibody-drug conjugates.
View company